UPTDinactive

ESTRELLA IMMUNOPHARMA, INC.

Healthcare·Oncology·Phase 1
OncologyGene TherapyInfectious Disease

ESTRELLA IMMUNOPHARMA, INC. (UPTD): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.

4.7/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ESTRELLA IMMUNOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Pipeline (1 candidate)

DrugPhase
eb103Phase 1/Phase 2
1 clinical trial·CEO: Cheng Liu

Frequently asked questions

How many drug candidates are in ESTRELLA IMMUNOPHARMA, INC.'s pipeline?

ESTRELLA IMMUNOPHARMA, INC. (UPTD) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is ESTRELLA IMMUNOPHARMA, INC.'s lead drug candidate?

ESTRELLA IMMUNOPHARMA, INC.'s most advanced tracked candidate is eb103 (Phase 1/Phase 2) for B-Cell Non-Hodgkin's Lymphoma (NHL).

Who is the CEO of ESTRELLA IMMUNOPHARMA, INC.?

Cheng Liu is the chief executive officer of ESTRELLA IMMUNOPHARMA, INC. (UPTD).

Get the full picture on ESTRELLA IMMUNOPHARMA, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar